NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD
NASDAQ:INZY (6/3/2025, 12:34:44 PM)
3.98
0 (0%)
The current stock price of INZY is 3.98 USD. In the past month the price increased by 145.37%. In the past year, price decreased by -14.15%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.19 | 330.04B | ||
AMGN | AMGEN INC | 13.95 | 155.71B | ||
GILD | GILEAD SCIENCES INC | 14.06 | 135.37B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.38B | ||
REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.26B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.89B | ||
ARGX | ARGENX SE - ADR | 100.9 | 35.43B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.46B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.46 | 27.24B | ||
NTRA | NATERA INC | N/A | 22.08B | ||
BIIB | BIOGEN INC | 8.4 | 19.47B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 14.89B |
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
INOZYME PHARMA INC
321 Summer Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Axel Bolte
Employees: 67
Phone: 18573304340
The current stock price of INZY is 3.98 USD.
The exchange symbol of INOZYME PHARMA INC is INZY and it is listed on the Nasdaq exchange.
INZY stock is listed on the Nasdaq exchange.
15 analysts have analysed INZY and the average price target is 13.77 USD. This implies a price increase of 245.98% is expected in the next year compared to the current price of 3.98. Check the INOZYME PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INOZYME PHARMA INC (INZY) has a market capitalization of 256.95M USD. This makes INZY a Micro Cap stock.
INOZYME PHARMA INC (INZY) currently has 67 employees.
INOZYME PHARMA INC (INZY) has a support level at 3.96 and a resistance level at 3.98. Check the full technical report for a detailed analysis of INZY support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INZY does not pay a dividend.
INOZYME PHARMA INC (INZY) will report earnings on 2025-08-04, before the market open.
INOZYME PHARMA INC (INZY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
The outstanding short interest for INOZYME PHARMA INC (INZY) is 6.07% of its float. Check the ownership tab for more information on the INZY short interest.
ChartMill assigns a technical rating of 9 / 10 to INZY. When comparing the yearly performance of all stocks, INZY is one of the better performing stocks in the market, outperforming 98.31% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to INZY. INZY has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months INZY reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -24.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -112.14% | ||
ROE | -335.61% | ||
Debt/Equity | 0.65 |
ChartMill assigns a Buy % Consensus number of 85% to INZY. The Buy consensus is the average rating of analysts ratings from 15 analysts.